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EFFECTS OF AGING AND DIET ON NEPRILYSIN ACTIVITY 
ETHAN KALLICK 
ABSTRACT 
 Neprilysin (NEP) is an endopeptidase with several vasoactive substrates, 
including natriuretic peptides. A NEP inhibitor combined with an angiotensin receptor 
blocker (LCZ696) improves outcomes in patients with heart failure with reduced ejection 
fraction (HFrEF); however, it has not been tested in patients with HF with preserved 
ejection fraction (HFpEF).  Two common forms of HFpEF are caused by aging and 
metabolic syndrome (MetS)/type 2 diabetes. Therefore, the goal of this study was to 
determine whether NEP activity is increased in mice with diastolic dysfunction due to 
aging or MetS.   
C57BL/6J mice were fed normal chow diet (NCD) for the first two months of 
their life, before being switched to either control diet (CD) or a high fat, high sucrose 
(HFHS) diet for 4 or 16 months, which allowed for determination of the effects of both 
age and diet on NEP activity.  NEP activity was measured in plasma based on the 
generation of a fluorescent product, methoxy-2-naphthylamine (MNA). Samples were 
incubated +/- NEP inhibitor thiorphan to distinguish NEP activity from activity of other 
non-specific endopeptidases. The difference in fluorescence of MNA was then measured, 
and samples incubated with thiorphan were subtracted from samples incubated without 
thiorphan to give plasma NEP activity.  Baseline NEP activity values (BL, 5.0±2.9) were 
derived from 2 month old mice fed Normal Chow Diet (NCD).  Several mice were not 
switched to CD or HFHS, but were instead kept on NCD for an additional 4 months to act 
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as an age-matched control against the CD cohort, for determination as to whether CD had 
a differential effect on NEP activity relative to NCD. The mice switched to CD had 
increased NEP activity at 6 months compared to NCD-fed mice (14.8±6.4; p<0.0002 vs. 
BL).  For this reason, mice were fed CD for all subsequent experiments.  NEP activity in 
CD-fed mice increased from 4 months to 16 months (14.8±6.4 vs. 65.3±16.4; p= 0.0028).  
NEP activity in HFHS-fed mice increased from 4 months to 16 months as well (20.0±7.6 
vs. 43.8±20.9; p= 0.0031) Comparison of the age-matched effect of HFHS diet relative to 
CD revealed that there was a trend towards significance at 4 months (20.7±7.6; p=0.06 
vs. CD) but not at 16 months (43.8±20.9; p=ns vs. CD).   
This study revealed that both CD and HFHS increase NEP activity compared to 
NCD, perhaps as a result of the lard (saturated fat) as the principal source of fat in those 
diets.  More importantly, it revealed that NEP activity increases with aging, and that 
aging exerts a greater influence on NEP activity than diet (MetS) does.  Finally, it was 
shown that LCZ696 can effectively lower plasma NEP activity.  Mice fed CD and HFHS 
diet for 16 months that received one week of 100 mg/kg LCZ696 therapy had 78% 
inhibition (p= 0.0286) and 85% inhibition (p= 0.0006 ) of their plasma NEP (sNEP) 
activity, respectively.    This strongly suggests the utility of LCZ696 as a promising 
treatment option for patients with aging and MetS-related HFpEF. 
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INTRODUCTION 
 Neprilysin (NEP) is a membrane-bound, zinc-dependent endopeptidase that is 
expressed ubiquitously including in heart, brain, peripheral nerves, lungs, vasculature, 
adrenal glands, lungs, epithelia, adipocytes, fibroblasts and neutrophils.  Membrane-
bound NEP has a large extracellular catalytic domain, a transmembrane region, and a 
short cytoplasmic N-terminal domain (Erdos & Skidgel, 1989; Maguer-Satta, Besançon, 
& Bachelard-Cascales, 2011).  Importantly, NEP exists in soluble form (sNEP) in 
plasma, Cerebrospinal Fluid (CSF), and urine (Bayes-Genis, Barallat, & Richards, 2016), 
and retains its catalytic activity (Spillantini et al. 1990; Yandle et al. 1992).  The process 
whereby NEP goes from its tissue-based, membrane-bound form to become solubilized 
(sNEP) is ultimately unknown, but it is theorized that NEP undergoes ectodomain 
shedding, which entails proteolytic cleavage of its extracellular domain (Bayes-Genis, 
2015).  In addition to the soluble form (sNEP), NEP in plasma exists on the neutrophil 
plasma membrane where it cleaves the chemotactic peptide fMet-Leu-Phe, and likely has 
a role in modulating neutrophil chemotaxis (Roques et al. 1993; Connelly et al. 1985). 
NEP is also referred to as neutral endopeptidase, CD10, enkephalinase, common acute 
lymphoblastic leukemia antigen, and endopeptidase 24.11 (Bayes-Genis, 2015); however, 
for the purposes of this thesis, it will be referred to solely as Neprilysin (NEP). 
NEP is composed of 749 amino-acid residues (Oefner et al. 2000).  NEP is 
encoded by chromosome 3 (3q21-27) and spans more than 80 kb, with its messenger 
RNA (mRNA) containing 24 exons (Li et al. 1995; Tiraboschi et al. 1999; D’Adamio et 
al. 1989).  Notably, the peptide sequence His-Glu-Ile-Thr-His is responsible for enzyme 
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binding and substrate catalysis, and is encoded within exon 19 (D’Adamio et al. 1989).  
NEP contains a single zinc atom, coordinated by residues of Histidine and Glutamic acid, 
and is crucial for catalytic activity.  NEP is restricted by its small catalytic site to cleaving 
small peptides with a molecular weight below 3,000 Da (Pankow et al. 2009).  
Proteolytic activity has been characterized as NEP having a special preference for the 
amino side of hydrophobic amino acids; specifically, Phenylalanine or Leucine at the P1 
position (Bayes-Genis, Barallat, & Richards, 2016). 
 NEP has over 50 substrates, both in vitro and in vivo (table 1) (Bayes-Genis, 
Barallat, & Richards, 2016); given the wide-ranging distribution of NEP in various 
tissues coupled with its myriad substrates, it is clear that NEP plays a role in both health 
and disease.  Within the context of Heart Failure (HF), Atrial Natriuretic Peptide (ANP), 
B-type Natriuretic Peptide (BNP), C-type Natiuretic Peptide (CNP), Angiotensin 2, 
Endothelin, Bradykinin, and Adrenomedullin are NEP’s salient substrates and will 
therefore, be the ones focused on.  Much of the clinical impact of NEP inhibition is 
assumed to be due to augmentation of Natriuretic Peptide (NP) activity (Bayes-Genis, 
Barallat, & Richards, 2016) and as such, special attention will be given to the natriuretic 
peptides (NPs) given their known cardiovascular effects. 
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Cardio-renal ANP, BNP, CNP; Angiotensin 1, 2, 3, 1-
9; Endothelin-1, -2, -3; Adrenomedullin, 
Bradykinin 
Nervous System Amyloid-beta; Enkephalins; alpha-
Endorphin, gamma-Endorphin; alpha-
Neoendorphin, beta-Neoendorphin; 
Nociceptin; Corticotropin-releasing 
factor; Luteinizing hormone-releasing 
hormone; Oxytocin; Antidiuretic 
Hormone; Neurotensin; Neuropeptide Y 
Gastrointestinal Gastrin-releasing peptide; Gastric 
inhibitory peptide; vasoactive intestinal 
peptide; cholecystokinin 
Respiratory Substance P 
Metabolic Glucagon; Glucagon-like peptide; beta-
lipotropin; insuin beta-chain; secretin; 
somatostatin 
Table 1.  Neprilysin substrates.  Neprilysin (NEP) has various substrates in multiple 
tissues (adapted from Bayes-Genis, Barallat, & Richards, 2016).   
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Natriuretic Peptides 
 There are three major natriuretic peptides (NPs): atrial natriuretic peptide (ANP), 
B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).  NPs are released 
in response to pressure and volume overload, and act to protect the cardiovascular system 
from the deleterious effects of such hemodynamic overload by swiftly inducing diuresis, 
natriuresis, kaliuresis, vasodilation, and inhibiting the renin-angiotensin-aldosterone 
system (RAAS).  It is well known that tonic activation of RAAS leads to pathologic 
cardiac remodeling via induction of cardiac myocyte hypertrophy, and interstitial fibrosis 
(Kim et al. 1995; Konstam et al. 1992); therefore, NPs play a very important 
counterregulatory role in preventing RAAS-mediated pathology and maintaining 
homeostasis.  Several models elucidate this point via inactivation of NP bioactivity, either 
via NP-specific knockout or NP receptor knockout model, showing the deleterious 
cardiac effects of NP insufficiency.  An ANP receptor (NPR-A) knockout mouse model 
showed significantly depressed systolic and diastolic function, interstitial fibrosis, and a 
shift in cardiac gene expression towards upregulation of pro-hypertrophic markers 
correlating to profound cardiac hypertrophy that resulted in a 61% increase in heart 
weight compared to control (Kuhn et al. 2002). Similarly, exogenous BNP administration 
to HF patients in a number of randomized, controlled clinical trials resulted in a number 
of improvements in cardiac parameters including decreases in right atrial pressure, 
pulmonary artery pressure, pulmonary wedge pressure, mean arterial pressure, 
pulmonary/vascular resistance, and increased cardiac index as well as improvements in 
HF symptoms such as dyspnea and fatigue (Marcus et al. 1996; Yoshimura et al. 1991; 
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Mills et al. 1999).  Impressively, Colucci et al. found that BNP reduced average 
pulmonary wedge pressure by 10 mm Hg and increased cardiac index by 400 mL/min per 
square meter (Colucci et al. 2000). 
   Perhaps most relevant to this thesis is the positive effects of NPs on the cyclic 
guanosine monophosphate (cGMP)- protein kinase G (PKG) pathway.  Binding of NPs to 
NPR-A and NPR-B stimulate particulate guanylate cyclase to synthesize cGMP, which 
activates PKG and leads to positive effects on cardiomyocyte compliance and ultimately, 
diastolic function (Marso et al. 2016).  Such effects will be discussed extensively in 
subsequent sections.  
ANP and BNP are both of cardiac origin, with ANP being primarily synthesized 
in atrial myocytes and BNP deriving primarily from the ventricles.  Notably, ANP and 
BNP can be released from any chamber of the heart under pathologic conditions (Daniels 
& Maisel, 2007).  ANP is synthesized and stored in granules until atrial distention 
triggers its release; indeed, ANP is released in response to even minor physiologic 
circumstances of increased preload, such as exercise.  In addition to its diuretic, 
natriuretic, kaliuretic, and vasodilatory actions, ANP acts as an important counter-
regulator to RAAS via its ability to attenuate renin, angiotensin II, aldosterone, and 
sympathetic nervous system activity (Cuneo et al. 1987; Schultz et al. 1988); thus, in 
addition to maintaining cardiorenal homeostasis, ANP is critical to blocking acute 
activation of several of the pathophysiological mechanisms seen in HF. 
BNP is directly synthesized de novo and secreted from the ventricular myocyte in 
bursts as pre-proBNP, in response to increased ventricular wall tension resulting from 
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volume expansion (Pandit et al. 2011).  Subsequently, pre-proBNP is cleaved to pro-
BNP1-108 and then further processed to its biologically active form BNP1-32 and the 
inactive amino-terminal fragment NTproBNP (Daniels & Maisel, 2007).  Given the 1:1 
secretion of BNP and NTproBNP, both BNP and NTproBNP can be reliably used in the 
setting of measuring ventricular dilatation that is seen in the failing heart. 
CNP is released primarily from the systemic endothelium in response to shear 
vascular stress (McFarlane, Winer, & Sowers, 2003) or circulating ANP or BNP 
(Okahara et al. 1995; Stingo et al. 1992), but can also be synthesized and released by 
cardiac myocytes (Daniels & Maisel, 2007) and renal glomerular and tubular cells 
(Mattingly et al. 1994). CNP lacks natriuretic function, instead acting locally via 
paracrine mechanism to induce vasodilation and inhibit hyperplasia of the vasculature, 
glomerulus, and interstitial matrix (McFarlane et al., 2003).  Moreover, there is evidence 
that CNP plays a role in long bone growth and development, as studies have shown that 
CNP-deficient mice exhibit dwarfism and suffer early death compared to their wild-type 
(WT) counterparts (Chusho et al. 2001).   
 NPs exert their effects on target tissues via binding and activation of membrane-
bound natriuretic peptide receptors (NPRs) that are in turn linked to intracellular second 
messenger cyclic guanosine monophosphate (cGMP)-dependent signaling cascade 
(Potter, 2011).  As such, cGMP activation upon NP binding is responsible for a cell’s 
physiologic response to NP stimulation.  ANP and BNP exert their physiologic effects via 
Natriuretic Peptide Receptor-A (NPR-A), while CNP action is mediated through NPR-B.  
NPR-C is responsible for clearing all three NPs from systemic circulation; research has 
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shown that NPR-C clears 50% of NPs from circulation, while the other half of circulating 
NPs are enzymatically degraded by NEP (McFarlane et al. 2003).  Given both the large 
physiologic role that NEP has in NP inactivation coupled with the positive cardiovascular 
effects of NPs, it is perhaps no surprise that NEP inhibition has risen to prominence as an 
important target in cardiovascular therapeutics.  Indeed, NEP inhibition and its effects 
will be expounded upon further; however, before delving into the role of NEP in HF, it is 
necessary to briefly delineate HF and its pathophysiology. 
 
Heart Failure 
Heart Failure (HF) is a complex clinical condition whereby the heart is incapable 
of sustaining a Cardiac Output (CO) that is sufficient to meet the metabolic demands of 
the body’s tissues (Kemp & Conte, 2012).  Generally speaking, HF arises as a result of 
structural and functional deficits of the myocardium that results in compromised ejection 
of blood or ventricular filling (Inamdar & Inamdar, 2016).  Such deficits are, on a 
structural level, result of loss of critical quantity of functional myocytes, often as the 
result of apoptosis, with subsequent replacement fibrosis of dead myocardial tissue 
(Kemp & Conte, 2012; Van Heerebeek et al. 2006).  Several pathophysiologic 
mechanisms can induce HF including genetic mutations, ischemic heart disease, 
hemodynamic overload, ventricular remodeling, interstitial fibrosis, excessive 
neurohumoral activation, abnormal cardiac myocyte calcium cycling, or myocyte 
apoptosis (Dassanayaka & Jones, 2015).  These mechanisms are not mutually exclusive; 
instead, many of them can, and often do, occur in concert.   
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In addition to cardiac dysfunction, it is important to note the relevance of several 
maladaptive neurohumoral mechanisms that become constitutively activated during HF.  
Decreased CO in the failing heart results in baroreceptor hypoperfusion, which triggers 
compensatory activation of the sympathetic nervous system (SNS).  Tonically increased 
SNS activity combined with renal hypoperfusion leads to activation of RAAS.  Initially, 
these compensatory mechanisms are beneficial: increased SNS activity directly 
stimulates the heart, increasing CO by means of augmenting heart rate (HR) and stroke 
volume (SV); simultaneous induction of peripheral vasoconstriction increases mean 
arterial pressure (MAP), which is further beneficial.  RAAS, in addition to its synergistic 
effects in stimulating peripheral vasoconstriction, induces renal sodium reabsorption that 
expands extracellular volume (ECV) and increases preload, leading to augmented CO via 
Frank-Starling mechanism (Kemp & Conte, 2012; Patterson & Adams, 1996). 
As previously stated, these maladaptive neurohumoral mechanisms are initially 
beneficial in improving the cardiovascular and hemodynamic deficits seen in HF.  
However, with time, chronic neurohumoral activation further hastens the disease process 
and therefore, is particularly relevant to both understanding and treating the 
pathophysiology of HF.  Tonic SNS activation leads to constitutive activation of 
adrenergic receptors β1, β2, and α1 that eventually leads to myocardial toxicity via 
induction of fetal gene programme, myocyte hypertrophy, and apoptosis (Colucci, 1998).  
Similarly, tonic RAAS activation also leads to myocyte hypertrophy and interstitial 
fibrosis (Kim et al.1995; Konstam et al. 1992).  As such, historic HF therapies have 
largely been directed at attenuating these neurohumoral mechanisms; such therapies will 
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be further discussed within the framework of NEP inhibition therapy in subsequent 
sections. 
Clinically, HF is typically subdivided into Heart Failure with Reduced Ejection 
Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF) based 
upon measurement of Ejection Fraction (EF), the volumetric fraction of blood ejected 
from the heart with each heartbeat.  If EF is ≤ 50%, HF is considered HFrEF; conversely, 
HF with an EF ≥ 50% is considered HFpEF (Lekavich et al. 2015).   
 
Heart Failure with Reduced Ejection Fraction (HFrEF) 
HFrEF is characterized by a markedly decreased capacity of the left ventricle 
(LV) to supply the requisite amount of oxygenated blood to the rest of the body’s tissues 
that is satisfactory to their metabolic needs.  Phenotypically, the LV frequently dilates 
and acquires an eccentric configuration (Harada et al. 2017), leading to a reduced (or 
sometimes normal) LV mass/ end-diastolic volume ratio (Inamdar & Inamdar, 2016).  
HFrEF typically arises as result of pathological mechanisms that lead to large-scale 
cardiac myocyte loss or dysfunction, such as genetic abnormalities, myocardial infarction 
(MI), acute myocarditis, or myocardial toxicity (e.g. alcohol, drugs, chemotherapy) 
(Jessup et al. 2009). 
 
Heart Failure with Preserved Ejection Fraction (HFpEF) 
The hallmark of HFpEF is increased LV stiffness such that diastole is impaired 
and the heart cannot fully relax, leading to poor myocardial compliance and inability of 
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the LV to fill with blood.  Opposite to HFrEF, LV in HFpEF remodels to embody a 
concentric configuration (Shah, 2013), and has a high LV mass/ end-diastolic volume 
ratio (Ohtani et al. 2012).  LV wall thickness is typically significantly increased 
compared to both controls and the HFrEF patient cohort (Borlaug & Redfield, 2011).  On 
a microscopic level, this translates to cardiomyocyte hypertrophy with an average 
increase in size of 50% coupled with interstitial fibrosis (Van Heerebeek et al, 2006).  
Notably, HFpEF frequently arises as a result of hypertension, aging, and disordered 
metabolism, which includes dyslipidemia, metabolic syndrome (MetS), and type 2 
diabetes mellitus (T2DM) (Packer & Kitzman, 2018). 
The relationship between aging and cardiac dysfunction is well established, and 
there are several biological mechanisms that precede HFpEF often seen in aging: age-
related oxidative and mitochondrial stress triggers apoptosis, necrosis, and autophagy that 
leads to myocyte death.  Subsequently, there is induction of compensatory remodeling 
characterized by biochemical shifts that include increased myofibroblast synthesis and 
collagen deposition via transforming growth factor β-signaling (Upadhya & Kitzman, 
2017).  Furthermore, the equilibrium between matrix metalloproteinases (MMPs) and 
tissue inhibitors of matrix metalloproteinases (TIMPs) becomes perturbed, with 
downregulation of MMPs and upregulation of TIMPs, ultimately leading to increased 
extracellular matrix (ECM) and collagen type I accumulation (Weber, Brilla, & Janicki, 
1993; Ahmed et al. 2006).  Moreover, there is often age-related mitochondrial 
dysfunction, which on an ultrastructural level, leads to decreased functionality of several 
key mitochondrial components (Dai & Rabinovitch, 2009; Vermulst et al. 2008; 
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Vermulst et al. 2007); this is compounded by declining effectiveness of macroautophagy 
(or mitophagy), the process whereby dysfunctional mitochondria are eliminated (Taneike 
et al. 2010; Terman et al. 2010).   
In sum, these age-related structural and biochemical changes ultimately lead to 
significant structural remodeling in the heart and vasculature that includes increased LV 
wall thickness and fibrosis that precedes diastolic dysfunction, and in many people, 
HFpEF (Chantler & Lakatta, 2012).  As such, it is unsurprising that HFpEF is almost 
exclusively found in older people, particularly women (Upadhya et al. 2015), in whom 
90% of new HF diagnoses are HFpEF (Gottdiener et al. 2000). 
In addition to age-related effects, metabolic disorders such as dyslipidemia, MetS, 
and T2DM are frequently associated with MetS-related cardiomyopathy that is 
characterized by myocyte hypertrophy, interstitial fibrosis, and mitochondrial dysfunction 
(Sverdlov et al. 2016); such dysfunction closely resembles the clinical HFpEF syndrome.  
Certainly, obesity is a common comorbidity in HF regardless of EF status; this is 
highlighted by data from the Framingham Heart Study, which showed that, after 
adjusting for established risk factors, there was a 5% and 7% increase in HF risk for men 
and women, respectively, for each unit increase in BMI (Prenner & Mather, 2018).  
Further, once HF begins, BMI is strongly correlated with worse cardiac function and 
prognosis (Dalos et al. 2016).  However, obesity and disordered metabolism are 
especially associated with HFpEF.  The average body mass index (BMI) of HFpEF 
patients enrolled in clinical trials almost invariably exceeds 25 kg/m2 and more often 
exceeds 30 kg/m2 (Prenner & Mather, 2018).  In fact, more than 80% of HFpEF patients 
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are overweight or obese (Haass et al. 2011).  Obesity and associated MetS largely drive 
HFpEF through their effects on increasing systemic inflammatory mediators that 
ultimately, promote myocardial stiffness and cardiac dysfunction (Paulus & Tschope, 
2013).  With increased adiposity, there is pronounced macrophage infiltration of adipose 
tissue, leading to increased release of pro-inflammatory cytokines (Taube et al. 2012); 
this theory is corroborated by increased inflammatory markers such as high sensitivity c-
reactive protein (CRP) and soluble interleukin 1 receptor-like 1 (ST-2) in HFpEF patients 
when compared to both HFrEF patients and hypertensive patients (Sanders-van Wijk et 
al. 2015; Collier et al. 2011).  Increased cytokines induce increased myocardial 
expression of several adhesion proteins such as vascular cellular adhesion molecule 
(VCAM) and E-selectin that promote migration of leukocytes secreting TGF- β, which 
induces conversion of fibroblasts into myofibroblasts that secrete increased amounts of 
collagen (Upadhya & Kitzman, 2017).  Ultimately, this leads to profound ECM changes 
that include enhanced deposition of collagen type I and more collagen cross-linking 
(Prenner & Mather, 2018).  These pathologic changes are directly linked with LV 
stiffness and diastolic dysfunction characteristic of HFpEF (Westermann et al. 2011; 
Kasner et al. 2011). 
Similarly, it is postulated that systemic inflammation as result of obesity/MetS 
further contributes to myocardial stiffness and diastolic impairment via disruption of 
endothelial nitric oxide (NO) release.  Normally, NO is a potent stimulator of the cGMP-
PKG pathway (Papp et al. 2018); however, depressed NO bioavailability means that the 
cGMP-PKG pathway is not properly activated (Neal et al. 2017), and the physiologic 
  13
process of cGMP-activated PKG phosphorylation of myocardial titin is disrupted.  This is 
significant because PKG phosphorylation of titin is known to lower cardiac myocyte 
stiffness, promoting myocardial compliance (Marso et al. 2016).  Indeed, the decreased 
cGMP levels and PKG activity seen in obesity/MetS leads to disruption of this 
physiologic process and is directly associated with increased cardiac myocyte stiffness, 
leading to the HFpEF phenotype (van Heerebeek et al. 2012).  This theory is supported 
by animal model of HFpEF as well as myocardial biopsy of HFpEF patients, that both 
showed decreased myocardial cGMP levels and PKG activity (Franssen et al. 2016; 
Prenner & Mather, 2018).   
Diabetes (T2DM) is also a significant risk factor for HFpEF.  Similar to the 
overwhelming incidence of obesity/MetS in HFpEF, there is a very high prevalence of 
diabetes in HFpEF: data from the CHARM trial showed that among patients with HFpEF, 
40% had a diabetes diagnosis, 20% had pre-diabetes, and 22% had undiagnosed diabetes 
(Papp et al. 2018).  This phenomenon is due, in large part, to the same mechanisms that 
cause HFpEF in MetS.  In a ZSF1 diabetic rat model, that also had comorbid obesity and 
hypertension, there was development of HFpEF secondary to titin hypophosphorylation 
(Fang, Prins, & Marwick, 2004).  Further, there is evidence that increased myocardial 
inflammation induces formation of reactive oxygen species (ROS) that oxidize and 
inactivate several biomolecules; notably, diabetics have been shown to have increased 
oxidation of soluble guanylate cyclase (sGC), cGMP, and PKG, making these molecules 
unresponsive to the beneficial effects of NO activation (Papp et al. 2018; Upadhya et al. 
2017). 
  14
Epidemiology 
HF has become increasingly prevalent in modern society, and was deemed an 
epidemic in 1997 based upon its dramatically increased incidence (Roger, 2013).  Overall 
prevalence for HF in developed countries is estimated to be 1-2% with an annual 
incidence of 5-10 new cases per 1000 individuals (Mosterd & Hoes, 2007).  In the United 
States alone, there are approximately 5.8 million cases of HF (Roger, 2013) with a yearly 
incidence of 670,000 cases among US Citizens over 45 years old (Konstantinou, 
Chatzizisis, & Giannoglou, 2013).  A comprehensive review conducted by Lloyd-Jones et 
al. found that one of every five persons at age 40 in the United States will develop HF at 
some point in their lifetime (Lloyd-Jones et al. 2010).  Despite significant advancements 
in understanding the pathophysiological underpinnings of HF, prognosis remains poor 
with five-year and ten-year mortality rates of 50% and 10%, respectively (Macintyre et 
al. 2000; Mosterd et al. 2001; Cowie et al. 2000).   
It is important to note the relevance of both the aging population and the obesity 
pandemic; currently, there is a greater percentage of people than ever before expected to 
reach age 80 (Crimmins, 2015), and obesity rates are projected to continue increasing 
substantially over the next two decades, with an estimated 33% and 130% in obesity and 
severe obesity prevalence, respectively (Finkelstein et al. 2012).  As such, HFpEF has 
become a particularly salient problem and will continue to have a rising incidence; 
currently, HFpEF represents half of all HF diagnoses (Yancy et al. 2006) and its 
prevalence relative to HFrEF is growing at a rate of 1% per year (Owan et al. 2006).  By 
2020, HFpEF prevalence is expected to exceed 8% of all people older than 65 years old, 
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and is expected to greatly increase in younger persons due to the uncontrolled pandemic 
of obesity (van der Velden, van der Wall, & Paulus, 2016).  This growing problem, due 
largely to the aging population and the “western diet” that has become pervasive in 
society, highlights the need to better understand the pathophysiology of HFpEF as well as 
determine novel therapeutic targets for its treatment. 
 
Role of Neprilysin in Heart Failure 
NEP has risen to prominence as a target in cardiovascular therapeutics, largely as 
a result of very promising data showing the effects of NEP inhibitior sacubitril combined 
with angiotensin receptor blocker (ARB) valsartan for the treatment of HFrEF.  This 
novel 1:1 molar combination of sacubitril/valsartan is referred to in literature as LCZ696, 
and is marketed by Novartis as Entresto.  The PARADIGM-HF (Prospective Comparison 
of Angiotensin Receptor Neprilysin Inhibitor (ARNi) with ACE Inhibitor (ACEi) to 
Determine Impact on Global Mortality and Morbidity in Heart Failure) was the largest 
and most geographically diverse HFrEF trial ever, whereby 8,442 patients with HFrEF 
(EF ≤ 40%, subsequently changed to EF ≤ 35% via amended protocol) and New York 
Heart Association (NYHA) class II-IV were randomized to receive either 200 mg ARNi 
LCZ696 b.i.d. (4,187 patients) or 10 mg ACEi enalapril (4,212 patients) b.i.d. 
(McMurray et al. 2013;  Bayes-Genis, 2015; Hubers & Brown, 2016).  Indeed, the 
treatment arm receiving LCZ696 had a reduction of 25% in risk of cardiovascular death 
and 19% in risk a primary endpoint (Solomon et al. 2016).  Furthermore, the LCZ696 
cohort had a 21% reduction in risk of hospitalization from HF (p< 0.001) and 
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significantly decreased physical limitations of HF symptoms (p=0.001) (McMurray et al. 
2014).  As such, the study was closed early after a median follow-up of 27 months as a 
result of excess reduced mortality because the boundary for an overwhelming benefit 
with LCZ696 had been reached (McMurray et al. 2014).   
Given the promise of sacubitril/valsartan (LCZ696) in improving clinical 
outcomes in HFrEF, subsequent studies have sought to see whether said therapy 
translates to HFpEF.  The prospective comparison of ARNi with ARB on management of 
heart failure with preserved ejection fraction (PARAMOUNT) trial was a randomized, 
multicenter trial that tested the hypothesis that 200 mg, twice daily LCZ696 is superior to 
160 mg, twice daily valsartan with regards to significantly reducing NT-proBNP levels in 
HFpEF patients (Solomon et al. 2012).  Given that NT-proBNP is not a substrate of NEP, 
it could be reliably measured as a marker of ventricular wall stress even in the presence 
of NEP inhibition via ARNi.  LCZ696 treatment cohort had significantly reduced NT-
proBNP levels after 12 weeks but the difference in levels was not sustained at 36 weeks 
(Huber & Brown, 2016).  Translational, cardiac effects of both treatment groups and 
correlation of NT-proBNP levels to cardiac phenotype were planned to be studied 
prospectively and such work is currently ongoing; however, of note, left atrial (LA) size 
significantly decreased in the LCZ treatment arm compared to the valsartan arm, with an 
average LA volume decrease of 4.6 mL vs. 0.37 mL, respectively (Hubers & Brown, 
2016).  The decrease in LA dimension is theorized to be a manifestation of reduced 
hemodynamic stress and improved LV filling pressures in patients receiving LCZ696 
(Hubers & Brown, 2016). 
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Furthermore, Prospective comparison of ARNi with ARB Global Outcomes in 
heart failure with preserved ejection fraction (PARAGON-HF) trial is another, more 
extensive multicenter clinical trial investigating the effects of LCZ696 vs. valsartan in 
improving the composite endpoints of cardiovascular death and HF hospitalizations 
(Solomon, 2017).  PARAGON-HF is currently ongoing and is expected to conclude in 
May, 2019 (clinicaltrials.gov).   
Several studies have suggested the utility of NEP as a novel biomarker in HF 
prognostication to predict cardiovascular mortality and morbidity; however, definitive, 
replicated data currently remains sparse.  A small trial (n= 350) showed that among 
patients hospitalized for acute HF, sNEP concentration at admission showed a clear trend 
towards significance for composite outcomes of HF hospitalizations and death at short-
term (2 months) and long-term (1.8 ± 1.2 years) follow-up (Bayes-Genis et al. 2015).  A 
larger, more encompassing study of 1,069 patients with mainly HFrEF by Bayes-Genis et 
al. showed that sNEP levels were predictive of CV hospitalization and death (Bayes-
Genis, Barallat, Galan et al. 2015).  Interestingly, a study of 144 HFpEF patients by 
Goliasch et al. reported that sNEP levels in their HFpEF patient cohort were 3-fold higher 
than in HFrEF, but showed no significant correlation with prognosis (Goliasch, Pavo, 
Zotter-Tufaro, et al., 2016). 
 
The Present Study 
We sought to determine the role that aging and obesity/MetS has on NEP activity.  
Given that LCZ696 has been so effective at improving outcomes with respect to all 
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clinical endpoints in HFrEF, we were interested to see if these effects translated to 
HFpEF, two common forms of which are caused by aging and MetS/T2DM.  Therefore, 
the goal of this study was to determine whether NEP activity is increased in mice with 
diastolic dysfunction due to aging or MetS.  We hypothesized that both aging and MetS 
increase NEP activity, contributing to the cardiac dysfunction phenotype seen in the aged 
and MetS patient populations. 
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SPECIFIC AIMS 
The aims of this thesis are twofold.  First, to provide laboratory data in an animal 
model showing the effect that aging and diet have on NEP activity, for determination as 
to whether aging and diet-induced obesity increase plasma NEP activity.  Second, to 
determine if LCZ696 can attenuate changes in NEP activity due to aging and diet-
induced obesity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  20
METHODS 
Animals and Diets 
Wild type (WT) C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME, 
USA) were fed normal chow diet (NCD) (Advanced Protocol® PicoLab® Verified 75 IF 
diet; Lab Diet, St. Louis, MO) for the first two months of their life.  At two months of 
age, mice were switched to either a control diet (CD) (product No. D09071703; Research 
Diets, Bar Harbor, ME) or high fat, high sucrose diet (HFHS) (product No. D09071703; 
Research Diets, Bar Harbor, ME) for 4 or 16 months.  Several mice (n=4) were not 
switched to CD or HFHS, but were instead kept on NCD for an additional 4 months to act 
as an age-matched control against the CD cohort, for determination as to whether CD had 
a differential effect on NEP activity relative to NCD.  
CD consisted of 10% kcal lard and 0% sucrose; HFHS consisted of 58% kcal lard 
and 13% kcal sucrose.  Diets were matched by nutrient/caloric value; full diet 
composition is provided in table 2.  Simplified breakdown of NCD, CD, and HFHS diets 
by macronutrient calorie (kcal%) is provided in table 3.  Mice were housed four per cage, 
with a 12 hour light/12 hour dark cycle.  Both food and water were provided ad libitum.  
The protocol was approved by the Institutional Animal Care and Use Committee at 
Boston University School of Medicine. 
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Table 2.  Control Diet (CD) and high fat, high sugar (HFHS) diet composition.  
D09071702 is HFHS diet and D09071703 is CD diet (Research Diets, Bar Harbor, ME).   
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% kcal Normal Chow 
Diet  
(NCD) 
Control Diet 
(CD) 
High Fat High 
Sucrose 
(HFHS) 
Protein 23 15 15 
Fat 13 
Soybean Oil 
10 
Lard 
58  
Lard 
Carbohydrate 64 
Mostly Starch 
75 
Corn Starch 
28 
Sucrose 
Table 3.  Diet composition and calorie (kcal%) breakdown.  NCD is Advanced 
Protocol® PicoLab® Verified 75 IF diet; Lab Diet, St. Louis, MO; CD is product no. 
D09071703; HFHS is product no. D09071702 (Research Diets, Bar Harbor, ME) 
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Neprilysin activity assays 
 Neprilysin activity assays were performed on plasma isolated at baseline from 2 
month old mice fed NCD (BL), and again from mice fed CD and HFHS diet following 4 
and 16 months of feeding.  NEP activity was also assayed in mice that remained on NCD 
for 4 additional months, being fed NCD for a total of 6 months.  Mice were anesthetized 
by placement in a bell jar chamber that contained isoflurane moistened paper, and 
incision was then made on the distal tail.  Heparinized capillary action blood tubes 
(Sigma Aldrich, St. Louis, MO) were then used to collect blood.  All samples were 
collected between 9 AM and noon.  Collected blood samples were centrifuged to obtain 
plasma, which was then stored at -80° C, without previous freeze-thaw cycles, prior to 
assay.   
 Neprilysin activity was measured via adapted protocol from Willard et al. 
(Willard et al. 2017). In the neprilysin activity assay, plasma samples were incubated 
with glutaryl-Ala-Ala-Phe-4-methoxy-2-naphthylamine (Glu-MNA) and Aminopeptidase 
M (APM).  Each plasma sample was assayed in both the presence and absence of the 
specific NEP inhibitor, DL-thiorphan, to distinguish plasma NEP activity from non-
specific endopeptidase activity.  Glu-MNA was broken down by plasma NEP (sNEP) 
into the intermediate, phe-4-methoxy-2-naphthylamine.  APM then degraded 
intermediate phe-4-methoxy-2-naphthylamine into the fluorescent product, methoxy-2-
naphthylamine (MNA), which was read via fluorescent plate reader and compared against 
an MNA standard curve.  A diagram of the neprilysin activity assay can be seen in figure 
1. 
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Figure 1.  Neprilysin Activity Assay.  Outline of NEP activity assay (adapted from 
Willard et al.) is shown, with relevant enzymes and substrates. 
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First, reagents were prepared to their final working concentrations.  Stock solution 
of 50 mM tris-HCl buffer was made.  MNA (Sigma-Aldrich, St. Louis, MO) was 
dissolved in DMF (dimethyl formamide) to 10 mM, then diluted with tris-HCl buffer to 1 
μM and stored at -20° C.  Glu-MNA (Sigma-Aldrich, St. Louis, MO) was dissolved in 
DMF to 10 mM and stored at -20° C until the day of the assay, whereby it was diluted 
with tris-HCl buffer to 1 mM.  DL-thiorphan (Sigma-Aldrich, St. Louis, MO) was 
dissolved in 100% ethanol to 10 mM, then diluted with tris-HCl buffer to 1 mM and 
stored at -20° C until the day of the assay, whereby it was diluted with tris-HCl buffer to 
25 μM.  Dithiothreitol (DTT; Sigma-Aldrich, St. Louis, MO) was diluted in dH2O to 11 
mM and stored at -20° C.  APM (R & D Systems, Minneapolis, MN) was diluted with 
tris-HCl buffer to final concentration of 1 μg/10μL. 
Neprilysin activity assay was conducted using a 96-well, half-area plate (Sigma-
Aldrich, St. Louis, MO).  Each plasma sample was assayed in triplicate, both in the 
presence and absence of DL-thiorphan.  Sample wells with added DL-thiorphan received 
3 μL of DL-thiorphan, 1 μL of APM, 14 μL  tris-Hcl buffer, and 5 μL plasma.  Sample 
wells without DL-thiorphan received 1 μL APM, 17 μL tris-Hcl buffer, and 5 μL plasma.  
96-well, half-area plate was then covered with sealing tape and placed on a plate shaker 
at 37° C for 10 minutes.  Subsequently, 2 μL Glu-MNA was added to all sample wells to 
achieve 80 μM final concentration.  Plate was recovered with sealing tape and put back 
on the plate shaker at 37° C for 30 minutes.  MNA standard curve was then created: 
MNA was diluted in tris-HCl buffer to create 100 μM MNA working stock.  100 μM 
MNA working stock was then added to an eppendorf tube in the following amounts to 
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create each MNA standard: 0 μL, 1.25 μL, 2.5 μL, 5 μL, 10 μL, 20 μL, 30 μL, and 60 μL.  
All tubes were were then filled with the corresponding volume tris-HCl buffer to create 
500 μL total volume.  This corresponded to 0, 6.25, 12.5, 25, 50, 100, 150, and 300 pmol 
MNA.  25 μL of each MNA standard was added in duplicate to the 96-well, half-area 
plate.  3.1 μL DTT was added to all wells containing either sample or standard.  Finally, 
fluorescence was read via fluorescent plate reader (Tecan Infinite® M1000 Pro 
Microplate Reader) with excitation wavelength of 340 nm and emission wavelength of 
420 nm.  Triplicate results were averaged and samples incubated with DL-thiorphan were 
subtracted from samples incubated without DL-thiorphan to give plasma NEP activity.  
Results were compared against the MNA standard curve, and expressed as pmol 
MNA/hour/μL plasma. 
 
Treatment with LCZ696 
Prior to LCZ696 treatment, plasma was isolated and frozen from mice fed CD and 
HFHS diet for 16 months, with accordance to the protocol outlined above.  Mice were 
then treated with 100 mg/kg LCZ696 for one week.  Mice water consumption was 
measured (figure 2) for approximation of LCZ696 concentration to put in water to 
achieve desired 100 mg/kg dose.  LCZ696 was then solubilized in drinking water and 
added to their cages for consumption ad libitum.  Immediately following one week of 
LCZ696 therapy, plasma was once again isolated according to the protocol outlined 
above.  NEP activity assay was performed on plasma samples from mice pre- and post-
treatment with 100 mg/kg LCZ696. 
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Statistical Analyses 
Comparison among diet groups: BL, NCD, CD, and HFHS was accomplished via 
one-way analysis of variance (ANOVA).  On several occasions, direct comparison 
between two groups was considered more appropriate and was performed via unpaired, 
non-parametric t-test (mann-whitney test).  P values < 0.05 were considered significant.  
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RESULTS 
As previously mentioned, NEP activity was measured and compared against an 
MNA standard curve, an example of which is shown in figure 3 below.  Baseline NEP 
activity (BL) was derived from mice fed Normal Chow Diet (NCD) for 2 months and 
averaged 5.0 ± 2.9 pmol MNA/hour/μL plasma.  Measurement of whether NEP activity 
was changed in the cohort that was not switched to CD or HFHS, but was instead kept on 
NCD for an additional 4 months to act as the age-matched control against the CD cohort 
was performed: mice that remained on NCD for 4 additional months had NEP activity of 
4.67 ± 0.7 pmol MNA/hour/μL plasma (p=ns vs. BL), whereas mice switched to CD for 4 
months following BL had NEP activity of 14.8 ± 6.4 pmol MNA/hour/μL plasma 
(p<0.0002 vs. BL).  For this reason, mice were fed CD for all subsequent experiments.  
These data are shown in figure 4. 
After being fed NCD for the first 2 months of their life (BL), mice were switched 
to either CD or HFHS diet for 4 or 16 months, which allowed for determination of the 
effects of both age and diet on NEP activity.  NEP activity in mice fed CD for 4 months 
was 14.8 ± 6.4 pmol MNA/hour/μL plasma and was further increased at 16 months on 
CD: 65.3 ± 16.4 pmol MNA/hour/μL plasma (p=0.0028).  NEP activity in mice fed 
HFHS for 4 months was 20.0 ± 7.6 pmol MNA/hour/μL plasma and was further 
increased at 16 months on HFHS diet: 43.8 ± 20.9 pmol MNA/hour/μL plasma (p= 
0.0031).  These results clearly highight the powerful effect of age on NEP activity.  
Comparison of the age-matched effect of HFHS diet relative to CD via unpaired non-
parametric t-test (mann-whitney test) revealed that there was a trend towards significance 
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at 4 months (p=0.06 vs. CD) but not at 16 months (p=ns vs. CD).  These data are shown 
in figure 5. 
Mice fed CD and HFHS for 16 months that received one week of 100 mg/kg 
LCZ696 therapy had 78% and 85% inhibition of their plasma NEP (sNEP) activity, 
respectively.  Prior to treatment with 100 mg/kg LCZ696, CD cohort had average NEP 
activity of 65.3±16.4 pmol MNA/hour/μL plasma; average NEP activity in this cohort 
decreased to 14.7 ± 9.6 pmol MNA/hour/μL plasma following one week of 100 mg/kg 
LCZ696 therapy (78% inhibition; p= 0.0286).  HFHS cohort had average NEP activity of 
43.8 ± 20.9 pmol MNA/hour/μL plasma prior to treatment with 100 mg/kg LCZ696; this 
decreased to 6.4 ± 4.6 pmol MNA/hour/μL plasma immediately following one week 100 
mg/kg LCZ696 treatment (85% inhibition; p= 0.0006).  Matched NEP activity values for 
individual mice pre- and post-treatment with 100 mg/kg LCZ696 are shown in figures 6 
and 7. 
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Figure 2. Water Consumption in Aged mice. Water consumption in the CD and HFHS 
diet cohorts was measured to best approximate the concentration of LCZ696 to add, such 
that the desired dosage of 100 mg/kg LCZ696 would be achieved. 
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Figure 3. MNA standard curve.  MNA standard curve was generated and utilized for 
determination of NEP activity in plasma samples with unknown NEP activity. r2 values < 
0.98 were not accepted. 
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Figure 4. Control Diet (CD) increases NEP activity.  Baseline NEP activity (BL, 
5.0±2.9) was derived from mice fed Normal Chow Diet (NCD) for 2 months.  NEP 
activity was not significantly increased in the NCD cohort at 6 months (4.67±0.72; p=ns 
vs. BL); after 2 months on NCD, mice were switched to CD for 4 months and exhibited 
increased plasma NEP activity (14.8±6.4; p<0.0002 vs. BL).  For this reason, mice were 
fed CD for subsequent experiments. 
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Figure 5. Aging exerts a greater influence on NEP activity than Metabolic 
Syndrome (MetS).  Mice fed HFHS diet for 4 or 16 months develop a MetS phenotype.  
Compared to mice fed CD, NEP activity trended towards an increase in mice fed HFHS 
at 4 months (20.0±7.6; p=0.06 vs. CD), but not at 16 months (43.8±20.9; p=ns vs. CD). 
NEP activity in CD-fed mice increased from 4 months to 16 months (14.8±6.4 vs. 
65.3±16.4; p= 0.0028) .  NEP activity in HFHS-fed mice increased from 4 months to 16 
months (20.0±7.6 vs. 43.8±20.9; p= 0.0031) 
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Figure 6. One week of treatment with 100 mg/kg LCZ696 significantly decreased 
plasma NEP activity in mice fed CD for 16 months.  NEP activity was measured in 
each mouse pre- and post-treatment with 100 mg/kg LCZ696.  Mice fed control diet (CD) 
for 16 months had elevated NEP activity compared to both BL and mice fed CD for 4 
months that was significantly decreased following one week of 100 mg/kg LCZ696 
therapy. 
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Figure 7. One week of treatment with 100 mg/kg LCZ696 significantly decreased 
plasma NEP activity in mice fed HFHS for 16 months.  NEP activity was measured in 
each mouse pre- and post-treatment with 100 mg/kg LCZ696.  Mice fed high fat, high 
sucrose diet (HFHS) for 16 months had elevated NEP activity compared to both BL and 
mice fed HFHS diet for 4 months that was significantly decreased following one week of 
100 mg/kg LCZ696 therapy. 
  36
DISCUSSION 
To our knowledge, this study is the first to have directly examined the effects of 
both aging and diet-induced MetS on plasma NEP activity.  This research demonstrated 
that NEP activity increases with aging, and that aging exerts a greater influence on NEP 
activity than MetS does.  Aging exerted a powerful effect on NEP activity, regardless of 
diet composition.  NEP activity in CD-fed mice increased from 4 months to 16 months on 
diet (14.8±6.4 vs. 65.3±16.4; p=0.0028), and NEP activity in HFHS-fed mice also 
increased from 4 months to 16 months on diet (20.0±7.6 vs. 43.8±20.9; p=0.0031).  An 
interesting finding of this study was that mice fed CD for 6 months had increased plasma 
NEP activity (14.8±6.4) compared to mice fed NCD for the same period (4.67±0.72).  It 
was then shown that both CD and HFHS increased NEP activity compared to NCD.  
Examination of the age-matched effect of HFHS diet relative to CD revealed a trend 
towards significance at 4 months (20.7±7.6; p=0.06 vs. CD) but not at 16 months 
(43.8±20.9; p=ns vs. CD).  Importantly, it was shown that LCZ696 can effectively 
attenuate plasma NEP activity.  Mice fed CD and HFHS diet for 16 months that received 
one week of 100 mg/kg LCZ696 therapy had 78% inhibition (p=0.0286) and 85% 
inhibition (p=0.0006) of their plasma NEP activity, respectively. 
 
Effect of Aging 
The present study found a clear relationship between aging and NEP activity, 
regardless of diet composition.  Mice in both the HFHS and CD-fed cohorts exhibited 
significantly increased plasma NEP activity as they progressed from 4 months on diet to 
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16 months on diet.  No prior study to date has directly examined the relationship between 
aging and plasma NEP activity, and certainly more work needs to be done in a human 
population; however, these results suggest that the increased NEP activity seen in aging 
could contribute, at least in part, to the cardiac dysfunction and HFpEF phenotype seen in 
aging.  Indeed, the effect of increased NEP activity is deleterious to the heart primarily as 
a result of its effect on augmenting NP degradation.  Given that NPs stimulate cGMP 
synthesis (Piggott et al. 2006), it is plausible to conclude that NP deficiency leads to 
reduced cGMP activation, which limits activation of the myocardial cGMP-PKG 
pathway.  Attenuated PKG activity leads to hypophosphorylation of titin at the N2B 
unique sequence, which causes increased cardiomyocyte stiffness, reduced compliance, 
and contributes to the HFpEF phenotype (Papp et al. 2018).  This theory is supported by a 
pioneering study from Franssen et al. showing that myocardial biopsy obtained from 
HFpEF patients exhibited reduced myocardial cGMP content and PKG activity (Franssen 
et al. 2016).  Further, experiments of short-term BNP administration and cGMP-
enhancing treatment with sildenafil in a large animal model have showed enhancement of 
PKG-mediated titin phosphorylation, and resulted in improvement of diastolic function 
(Zinman et al. 2015).   
 
Effect of CD diet 
An unexpected, but nonetheless important discovery in this study was that CD 
had a greater effect on NEP activity than NCD did.  Upon investigation into the 
composition of each diet (figure 3), it was determined that while they are roughly 
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equivalent in terms of caloric breakdown by macronutrient, NCD fat source (13% kcal) 
derives from soybean oil whereas CD fat (10% kcal) derives from lard.  Given that only 
14% of the fatty acids in soybean oil are saturated, soybean oil is a largely unsaturated fat 
source; in contrast, lard is 40% saturated fat, making it a much more concentrated source 
of saturated fat (Gunstone 1996).  The adverse effects of saturated fats on 
cardiometabolic health is well documented (Sacks et al. 2017), and a recent study by 
Zraika et al. found that prolonged exposure to the saturated fatty acid (FA) palmitate 
upregulated islet NEP activity, leading to reduced insulin pre-mRNA and ATP levels, 
oxidative/nitrative stress, attenuated potassium and calcium channel activities, and 
decreased glucose-stimulated insulin secretion (Zraika et al. 2013)  However, no research 
to date has examined the differential effects of saturated vs. unsaturated fat on plasma 
NEP (sNEP) activity, and it remains plausible that the deleterious effects of saturated fat 
on the heart are due, at least in part, to its effect on increasing plasma NEP activity.  
Certainly, this mandates further experimentation, as this study was not set up to 
determine such data.  
 
Effect of HFHS diet 
In this study, there was a lack of congruency in the results with regards to the role 
of obesity-related MetS on plasma NEP activity.  NEP activity in mice fed HFHS diet for 
4 months showed a trend towards significance (p= 0.06) compared to the CD-fed mice at 
4 months, but that trend was not present at 16 months.  However, both HFHS and CD-fed 
mice exhibited increased NEP activity compared to mice fed NCD, perhaps as a result of 
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the increased saturated fat content in those diets compared to NCD.  Interestingly, a 2011 
study by Standeven et al. found that in humans, plasma NEP concentrations were 
increased in patients with MetS.  Their study, which examined 318 white European 
males, found that MetS patients had elevated circulating plasma NEP levels, and 
increased progressively with degree of insulin resistance, body mass index (BMI), and 
increasing MetS components (Standeven et al. 2011).  Similarly, a study by Rice et al. 
also showed that plasma NEP concentration correlated significantly with BMI as well as 
with cholesterol, and triglycerides  (Rice et al. 2006).  A third very compelling study 
measured circulating NEP levels in bariatric (Roux-en-Y gastric bypass) surgery patients 
pre- and post-operation, and found that plasma NEP fell 27±16% following bariatric 
surgery, further reinforcing the probable notion that obesity-related MetS affects NEP 
activity in some capacity (Ghanim et al. 2018). 
Ultimately, the amalgamation of these results highlight the need for further work 
to be done to fully elucidate the role of diet, and specifically MetS, on NEP.  As 
previously stated, HFHS has an effect, and saturated fat may have a profound effect on 
plasma NEP activity.  If future work does find a more definitive link between MetS and 
NEP activity, it could help explain the phenomenon of low NP levels in obese patients 
compared to their normal weight counterparts despite having a similar degree of clinical 
HF (Prenner & Mather, 2018).  This phenomenon has traditionally been explained by the 
high concentration of the receptor that clears NPs from circulation, NPR-C, in adipose 
tissue coupled with the increased amounts of adipose tissue in obese patients, which 
ostensibly directly decreases circulating NP levels (Wang et al. 2004).  However, if a 
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clear link is established between increased plasma NEP activity in MetS patients, it could 
help mechanistically explain this phenomenon more completely.     
 
Inhibition by LCZ696 
There have been several prominent trials, notably PARADIGM-HF, that have 
established the effectiveness of LCZ696 in improving clinical outcomes in HFrEF 
patients.  However, to date, there has been very little research on LCZ696 as a therapy for 
HFpEF.  Given the established causal relationship of both aging and diet-induced obesity 
with HFpEF, this research is fundamental to better understanding and characterizing the 
role of plasma NEP activity in the pathogenesis of HFpEF.  Importantly, a central finding 
of this study was that LCZ696 could effectively attenuate the elevated plasma NEP 
activity seen in the aged mice fed CD (78% inhibition; p= 0.0286) and HFHS diet (85% 
inhibition, p=0.0006) for 16 months.  As such, using LCZ696 therapy in this patient 
cohort to decrease pathologically elevated NEP activity will lead to augmentation of NP 
levels (Bayes-Genis, Barallat, & Richards, 2016).  This will result in increased activation 
of the myocardial cGMP-PKG pathway, ultimately culminating in increased titin 
phosphorylation and improvements in cardiomyocyte compliance and ostensibly, the 
HFpEF phenotype. 
 
Limitations of the Study 
 As previously mentioned, this study was not set up to determine the differential 
effects of saturated fat vs. unsaturated fat on plasma NEP activity.  While we 
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hypothesized that CD and HFHS diet increased plasma NEP activity as a result of the 
increased saturated fat content in those diets relative to NCD, it is entirely possible that 
there were other confounding variables present that contributed to this result.  As such, 
the cornerstone of future work should focus on manipulating saturated fat content as the 
independent variable, with focus on how differential quantitation of fatty acid saturation 
in food contributes to both plasma NEP activity and diastolic function. 
Moreover, it should be noted that while several studies have examined plasma 
NEP levels, mostly in the context of MetS patients (Standeven et al., 2011; Rice et al., 
2006; Ghanim et al. 2018), very few studies to date have examined plasma NEP activity 
in any capacity.  Therefore, future work within this area of study should measure both 
circulating plasma NEP levels and plasma NEP activity as a means to better understand 
the relationship between the two.  Finally, and perhaps most importantly, future research 
should investigate plasma NEP activity in human populations with both MetS and aging, 
and directly correlate NEP activity to cardiac health and diastolic function, using clinical 
parameters. 
 
Clinical Implications 
 The beneficial effects of NP-mediated activation of the myocardial cGMP-PKG 
pathway on diastolic function highlight the relevance and promise of LCZ696 as a 
therapy for HFpEF patients.  Treatment with NEP inhibitors in healthy humans as well as 
HF patients has been shown to reliably and sustainably increase plasma NP 
concentrations as well as circulating and urine cGMP levels (Bayes-Genis, Barallat, & 
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Richards, 2016).  Honing and optimizing a therapy that can increase NP and cGMP levels 
via inhibition of NEP activity appears to be a very promising treatment option, especially 
in aged and MetS human patient populations that potentially exhibit significantly 
elevated plasma NEP activity; this sentiment is especially true in the age of precision 
medicine, whereby plasma NEP activity can be measured before decision as to whether 
the patient would benefit from NEP inhibition therapy.  Ultimately, data from this study 
suggest that aging exerts a powerful effect on NEP activity and diet appears to have an 
effect as well, albeit smaller and less well defined; certainly, more work needs to be done 
in both animal model and human populations to definitively elucidate the role of both 
aging and MetS on NEP activity.  Finally, to reiterate, LCZ696 remains an interesting, 
promising, and possibly very effective therapy for aging and diet-induced HFpEF, a 
growing and largely fatal disease that, thus far, has been defined by lack of effective 
therapies. 
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